Summit Therapeutics Jumps on $2 Billion AstraZeneca Investment
Source: Bloomberg ·
Summit Therapeutics Inc. shares rose after it said AstraZeneca Plc would make a $2 billion strategic equity investment in the cancer drugmaker to jointly develop drugs.
BestAIBroker analysis
Finance-aware sentiment: positive (+0.50 on a -1 to +1 scale).